The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients
Abstract
Objective. To evaluate an approach to the diagnosis and treatment of maple syrup disease (MSD). Methods. Family histories and molecular testing for the Y393N mutation of the E1α subunit of the branched-chain α-ketoacid dehydrogenase allow us to identify infants who were at high risk for MSD. Amino acid concentrations were measured in blood specimens from these at-risk infants between 12 and 24 hours of age. An additional 18 infants with MSD were diagnosed between 4 and 16 days of age because of metabolic illness. A treatment protocol for MSD was designed to 1) inhibit endogenous protein catabolism, 2) sustain protein synthesis, 3) prevent deficiencies of essential amino acids, and 4) maintain normal serum osmolarity. Our protocol emphasizes the enhancement of protein anabolism and dietary correction of imbalances in plasma amino acids rather than removal of leucine by dialysis or hemofiltration. During acute illnesses, the rate of decrease of the plasma leucine level was monitored as an index of net protein synthesis. The treatment protocol for acute illnesses included the use of mannitol, furosemide, and hypertonic saline to maintain or reestablish normal serum sodium and extracellular osmolarity and thereby prevent or reverse life-threatening cerebral edema. Similar principles were followed for both sick and well outpatient management, especially during the first year, when careful matching of branched-chain amino acid intake with rapidly changing growth rates was necessary. Branched-chain ketoacid excretion was monitored frequently at home and branched-chain amino acid levels were measured within the time of a routine clinic visit, allowing immediate diagnosis and treatment of metabolic derangements. Results. 1) Eighteen neonates with MSD were identified in the high-risk group (n = 39) between 12 and 24 hours of age using amino acid analysis of plasma or whole blood collected on filter paper. The molar ratio of leucine to alanine in plasma ranged from 1.3 to 12.4, compared with a control range of 0.12 to 0.53. None of the infants identified before 3 days of age and managed by our treatment protocol became ill during the neonatal period, and 16 of the 18 were managed without hospitalization. 2) Using our treatment protocol, 18 additional infants who were biochemically intoxicated at the time of diagnosis recovered rapidly. In all infants, plasma leucine levels decreased to <400 μmol/L between 2 to 4 days after diagnosis. Rates of decrease of the plasma leucine level using a combination of enteral and parenteral nutrition were consistently higher than those reported for dialysis or hemoperfusion. Prevention of acute isoleucine, valine, and other plasma amino acid deficiencies by appropriate supplements allowed a sustained decrease of plasma leucine levels to the therapeutic range of 100 to 300 μmol/L, at which point dietary leucine was introduced. 3) Follow-up of the 36 infants over >219 patient years showed that, although common infections frequently cause loss of metabolic control, the overall rate of hospitalization after the neonatal period was only 0.56 days per patient per year of follow-up, and developmental outcomes were uniformly good. Four patients developed life-threatening cerebral edema as a consequence of metabolic intoxication induced by infection, but all recovered. These 4 patients each showed evidence that acutely decreased serum sodium concentration and decreased serum osmolarity were associated with rapid progression of cerebral edema during their acute illnesses. Conclusions. Classical MSD can be managed to allow a benign neonatal course, normal growth and development, and low hospitalization rates. However, neurologic function may deteriorate rapidly at any age because of metabolic intoxication provoked by common infections and injuries. Effective management of the complex pathophysiology of this biochemical disorder requires integrated management of general medical care and nutrition, as well as control of several variables that influence endogenous protein anabolism and catabolism, plasma amino acid concentrations, and serum osmolarity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracellular Protein Catabolism and its Control During Nutrient Deprivation and Supply
Mortimore, G. E., & Pösö, A. R. (1987) · Annual Review of Nutrition · doi:10.1146/annurev.nu.07.070187.002543 · Cited by 458
Kinetics of Neutral Amino Acid Transport Across the Blood‐Brain Barrier
Smith, Q. R., Momma, S., Aoyagi, M., & Rapoport, S. I. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb01039.x · Cited by 454
Martin, J. H. (1989) · Cited by 295
Safety and Metabolic Effects of L‐Glutamine Administration in Humans
Ziegler, T. R., Benfell, K., Smith, R. J., Young, L. S., Brown, E., Ferrari‐Baliviera, E., Lowe, D. K., & Wilmore, D. W. (1990) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607190014004201 · Cited by 239
Chace, D. H., Hillman, S. L., Millington, D. S., Kahler, S. G., Roe, C. R., & Naylor, E. W. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.1.62 · Cited by 219
Interorgan amino acid nutrition
Christensen, H. N. (1982) · Physiological Reviews · doi:10.1152/physrev.1982.62.4.1193 · Cited by 192
McKean, C. M., Boggs, D. E., & Peterson, N. A. (1968) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1968.tb06202.x · Cited by 166
Dendritic Spine Pathology in Infants With Severe Protein-Calorie Malnutrition
Benítez-Bribiesca, L., la Rosa-Alvarez, I. D., & Mansilla‐Olivares, A. (1999) · PEDIATRICS · doi:10.1542/peds.104.2.e21 · Cited by 93
Cerebral edema causing death in children with maple syrup urine disease
Riviello, J. J., Rezvani, I., DiGeorge, A. M., et al. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81036-4 · Cited by 86
Newborn Screening for Maple Syrup Urine Disease (Branched-Chain Ketoaciduria)
Naylor, E. (1980) · Springer eBooks · doi:10.1007/978-3-642-67488-4_3 · Cited by 73
Cited by
Ruger, J. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17064-5 · Cited by 465
Goyanes, A., Madla, C. M., Umerji, A., Duran Piñeiro, G., Giraldez Montero, J. M., Lamas Diaz, M. J., Gonzalez Barcia, M., Taherali, F., Sánchez-Pintos, P., Couce, M.-L., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118497 · Cited by 292
Maple syrup urine disease: mechanisms and management
Blackburn, P., Gass, J., Pinto e Vairo, F., Farnham, K., Atwal, H., Macklin, S., Klee, E., & Atwal, P. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s125962 · Cited by 280
BCAA Metabolism and NH3 Homeostasis
Conway, M. E., & Hutson, S. M. (2016) · Advances in Neurobiology · doi:10.1007/978-3-319-45096-4_5 · Cited by 53
O'Reilly, D., Crushell, E., Hughes, J., Ryan, S., Rogers, Y., Borovickova, I., Mayne, P., Riordan, M., Awan, A., Carson, K., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12337 · Cited by 24
Metadata
- Authors
- Morton, D. H., Strauss, K. A., Robinson, D. L., Puffenberger, E. G., & Kelley, R. I.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2002-06-01
- Volume
- 109
- Issue
- 6
- Pages
- 999-1008
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2119203984
- Cited by
- 326
- References
- 18
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients. https://app.cochat.ai/papers/10.1542/peds.109.6.999
- The paper
- Morton, D. H., Strauss, K. A., Robinson, D. L., Puffenberger, E. G., & Kelley, R. I. (2002). Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients. Pediatrics. https://doi.org/10.1542/peds.109.6.999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.